Furthermore, compared with single‐agent chemotherapy, the IPSOS study showed that first‐line treatment with atezolizumab provided a survival benefit and reduced toxicity in NSCLC patients ineligible for platinum‐based chemotherapy without EGFR or ALK alterations.24 Here, ALK is linked to non-small cell lung carcinoma.